Physician

Bilal Ahmed, MD

According to 2025 Medicare claims, Bilal Ahmed, MD (NPI: 1093984411) practices hematology/oncology in the Lexington Park, MD market, with the plurality of this provider's patient population coming from Calvert, MD. This provider's primary affiliated billing organization is CALVERTHEALTH MEDICAL GROUP, LLC (NPI: 1386871390; TIN: 263828176) and primary practice location at 20678-4043.

Ahmed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 810 traditional Medicare patients, billed 68,617 HCPCS/CPT codes, and received $1,257,045 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,781 prescription claims across 290 beneficiaries totaling $4,169,493 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). DME data shows 31 claims. Open Payments data shows 2 records totaling $66. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $662,006 and ending at $1,257,045. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $603,822 to $4,169,493. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $8,969 and ending at $1,284.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	438	22,757	$662,006
2016	493	95,744	$995,010
2017	497	160,504	$1,266,717
2018	594	136,732	$1,554,458
2019	733	91,336	$1,084,486
2020	707	115,452	$1,452,835
2021	715	118,556	$1,364,027
2022	790	141,776	$1,609,072
2023	816	70,277	$1,116,045
2024	810	68,617	$1,257,045

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	67	402	$603,822
2016	126	618	$927,622
2017	156	800	$1,002,728
2018	163	916	$1,368,816
2019	200	998	$1,601,067
2020	214	1,380	$2,585,748
2021	214	1,192	$2,442,170
2022	236	1,290	$3,265,409
2023	245	1,467	$3,428,226
2024	290	1,781	$4,169,493

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	188	$9,180
2016	33	348	$14,482
2017	N/R	166	$11,792
2018	N/R	165	$6,977
2019	N/R	181	$9,987
2020	N/R	332	$26,915
2021	N/R	367	$12,576
2022	11	335	$9,495
2023	N/R	102	$11,930
2024	N/R	31	$760

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	117	283	$135
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	128	146	$131
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	72	72	$121
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	286	987	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	418	667	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	133	3,870	$672,808
Lumakras	Sotorasib	20	720	$513,392
Reblozyl	Luspatercept-Aamt	27	567	$354,654
Lenalidomide	Lenalidomide	24	672	$292,621
Kisqali	Ribociclib Succinate	17	476	$289,456

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$559
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$66	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bilal Ahmed, MD?

Tedicare shows public-source Medicare data for Bilal Ahmed, MD (NPI 1093984411), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bilal Ahmed, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bilal Ahmed, MD?

Bilal Ahmed, MD is linked to CALVERTHEALTH MEDICAL GROUP, LLC (billing NPI 1386871390) in the available physician profile data.

Does Bilal Ahmed, MD have Open Payments data?

Bilal Ahmed, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.